MediPharm Labs Enters Denmark Healthcare Cannabis Marketplace, Secures New White-Label Provide Prospects

bunch of red fruits

TORONTO, Sept. 01, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a worldwide leader in specialized, analysis-driven pharmaceutical-good quality cannabis extraction, distillation and derivative solutions, right now announced it will provide cannabis concentrate solutions in Denmark to two new healthcare cannabis clients below two separate white-label agreements. These clients will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ initially provide agreements for the export of completed solutions to Denmark.

Denmark granted sufferers legal access to cannabis-primarily based medicinal solutions two years ago as component of a 4-year pilot system. The system supplies sufferers with secure solution access and national well being authorities with patient information that they can use to recognize usage and efficacy. According to facts complied by New Frontier Information and the Danish Ministry of Overall health, more than two,one hundred sufferers (mostly girls amongst the ages of 42-64) received cannabis-primarily based medicinal solutions from 429 prescribing physicians below this system in 2019.

“The express goal of establishing a multi-jurisdictional, GMP-certified production capability is to lead the worldwide cannabis industry for medicinal, wellness and adult use applications and these agreements represent one more step forward in realizing our ambitions,” stated Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish healthcare industry with new and revolutionary healthcare cannabis focused solutions positions us for further development in Europe and adds to MediPharm Labs all-vital physique of information that we are leveraging to boost the style of our formulations for sufferers and buyers everywhere.”

Below the agreements, one particular which has an initial two-year term and the second a one particular-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil solutions that will be white-labeled for distribution.

MediPharm Labs anticipates delivery to its clients to start in October 2020, pending regulatory approval by applicable well being authorities.

GMP Certification Ignites Development for MediPharm Labs Australia

“Since the starting of 2020, MediPharm Labs Australia has secured various extremely eye-catching domestic and international provide agreements with higher good quality partners, now which includes new clients in Denmark,” stated Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new small business wins are a clear and vital validation of our choice to develop a GMP certified cannabis extraction facility provide chain for planet markets and a testament to MediPharm Labs increasing profile and reputation. We appear forward to ramping up production below all of these agreements.”

MediPharm Labs Australia received its Superior Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in May well 2020, which enables it to sell cannabis APIs and completed solutions to nations across the EU, which includes Denmark. The Corporation entered into its initially European white-label cannabis provide agreement that similar month with Therismos Restricted.

About Denmark’s Healthcare Cannabis Marketplace

Denmark launched its 4-year healthcare cannabis pilot system on January 1st, 20181. Post-harvest Superior Manufacturing Processes (GMP) is essential for distribution of healthcare cannabis solutions in Denmarktwo.

By way of the system, physicians can prescribe healthcare cannabis for all purposes and are guided by suggestions in 4 regions: discomfort brought on by a number of sclerosis, discomfort brought on by spinal cord harm, side effects from chemotherapy therapy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The suggestions published by the Danish Medicines Agency are primarily based on an in depth evaluation of literature as effectively as assessments of: cannabis schemes in the Netherlands, Canada and Israel prior cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical good quality cannabis oil and concentrates and sophisticated derivative solutions using a Superior Manufacturing Practices certified facility with ISO regular constructed clean rooms. MediPharm Labs has invested in an specialist, analysis-driven group, state-of-the-art technologies, downstream purification methodologies and goal-constructed facilities with 5 main extraction lines for delivery of pure, trusted and precision -dosed cannabis solutions for its clients. By way of its wholesale and white label platforms, they formulate, customer-test, method, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based solutions to domestic and international markets. As a worldwide leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.

For additional facts, please speak to:
Laura Lepore, VP, Investor Relations
Phone: 705-719-7425 ext 1525
E-mail: [email protected]
Site: www.medipharmlabs.com

______________________________
1 Medicinal Cannabis Pilot System. Retrieved: https://laegemiddelstyrelsen.dk/en/specific/medicinal-cannabis/citizens/medicinal-cannabis-pilot-programme/
two The Healthcare Cannabis Marketplace in Denmark &amp Europe. Retrieved: https://www.openaccessgovernment.org/the-healthcare-cannabis-industry-in-denmark-europe/80721/
three The Danish Healthcare Cannabis Pilot Programme: Placing the Patient Initially. Retrieved: https://www.healtheuropa.eu/the-danish-healthcare-cannabis-pilot-programme-placing-the-patient-initially/92991/

CAUTIONARY NOTE Concerning FORWARD-Hunting Information and facts:

This news release consists of “forward-hunting information” and “forward-hunting statements” (collectively, “forward-hunting statements”) inside the which means of the applicable Canadian securities legislation. All statements, other than statements of historical truth, are forward-hunting statements and are primarily based on expectations, estimates and projections as at the date of this news release. Any statement that includes discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or functionality (frequently but not usually applying phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that specific actions, events or benefits “may” or “could”, “would”, “might” or “will” be taken to take place or be accomplished) are not statements of historical truth and might be forward-hunting statements. In this news release, forward-hunting statements relate to, amongst other items, the thriving functionality of the agreements and shipping of solutions thereunder as planned further development in Europe and enhancing the style of formulations. Forward-hunting statements are necessarily primarily based upon a quantity of estimates and assumptions that, when regarded affordable, are topic to recognized and unknown dangers, uncertainties, and other components which might lead to the actual benefits and future events to differ materially from these expressed or implied by such forward-hunting statements. Such components involve, but are not restricted to: common small business, financial, competitive, political and social uncertainties the inability of MediPharm Labs to get sufficient financing the delay or failure to obtain regulatory approvals and other components discussed in MediPharm Labs’ filings, out there on the SEDAR internet site at www.sedar.com. There can be no assurance that such statements will prove to be correct, as actual benefits and future events could differ materially from these anticipated in such statements. Accordingly, readers need to not location undue reliance on the forward-hunting statements and facts contained in this news release. Except as essential by law, MediPharm Labs assumes no obligation to update the forward-hunting statements of beliefs, opinions, projections, or other components, need to they adjust.

Primary Logo

If You Liked This Write-up Click To Share

.mobile_tx{show: none}
#ax1x{
font-size: 1.1em
font-weight: bold
line-height: 1.five
clear:each
margin: 0px 0px 20px 1% !vital
min-height: four.5em
text-transform: uppercase
padding: .25em 10px
position: relative
width: 98%
float: left
}
.subsequent-pg {
height: 85px !vital
width: one hundred%
border-top rated-left-radius: 3px
border-bottom-left-radius: 3px
background-colour: #e5192c
background-image: url(‘/wp-content material/themes/mh-magazine/pictures/worldwide-just after.png’) !vital
background-repeat: no-repeat
background-position: appropriate center
background-size: auto one hundred%
overflow: hidden
box-sizing: border-box
margin-bottom: 0px
margin-top rated: 10px
position: relative
padding-left: 100px
}
.subsequent-pg::just before {
width: 45px !vital
height: 85px !vital
show: block
content material: “”
width: 32px
height: 64px
background-image: url(‘/wp-content material/themes/mh-magazine/pictures/worldwide-just before.png’) !vital
background-repeat: no-repeat
background-position: appropriate center
background-size: auto one hundred%
position: absolute
left: -4px
top rated: 0px
}
.action-txt {
text-transform: uppercase
margin: 12px
line-height: 61px
text-align: left
font-size: 36px
background-repeat: no-repeat
background-position: appropriate center
background-size: 26px 18px
colour: #FFF
float: left
font-weight: bold
font-household: “Open Sans”,sans-serif !vital
width: 78%
show: inline-block
text-align: center
}
@media (max-width: 768px){
.mobile_tx{show: block}
.desktop_tx{show: none}
.pps-slider-nav .pps-subsequent {
text-align: center
position: static
padding: 5px 20px
float: left
width: one hundred%
box-sizing: border-box
}
.pps-subsequent .subsequent-write-up-web page {
padding-left:
float: left
margin:
}
.subsequent-write-up-web page .action-txt {
padding-left: !vital
text-align: center
width: 87%
box-sizing: border-box
font-size: 26px
background:
text-align: center
}
#ax1x {
padding: .25em !vital
min-height: two.3em
width: one hundred% !vital
margin: 0px !vital
margin-bottom: 15px !vital
padding-bottom: !vital
}
}
@media (max-width: 500px){
.subsequent-write-up-web page .action-txt{
width: 75%
}
}

Latest posts